Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a type of bladder cancer called urothelial carcinoma, at a stage classified as cT2 to cT4, and who have given written agreement to take part in the study and follow its requirements.
- People whose treatment plan includes receiving a chemotherapy regimen containing cisplatin before having their bladder surgically removed.
- People who are willing to have three specialised MRI scans — one before treatment starts, one within 24 hours after the first cisplatin dose, and one after the chemotherapy course is completed.
Who may not be able to join:
- People who have previously had radiation therapy to the pelvic area.
- People who have serious kidney problems.
- People who have previously had open or keyhole surgery in the pelvic area.
- People who already have cancer that has spread to other parts of the body at the time of diagnosis.
- People who have a medical reason that makes it unsafe for them to have an MRI scan.
- People whose medical situation means they are not suitable to receive cisplatin chemotherapy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Amr Darwish, Lecturer, Urology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
Phone: +201101336409
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Predictive Value of Early mpMRI Biomarkers for Pathological Response to Neoadjuvant Chemotherapy in MIBC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.